You have read all your free articles, to continue reading subscribe to read the rest of this content.
The company announced last week that a major Nordic study will begin using their PET imaging agent ABY-025. ABY-025 is a novel Affibody molecule imaging tracer that can identify HER2 status in breast cancer patients. The researchers will be investigating a new ABY-025 based method developed at UpAlready a subscriber…
Oncopeptides present updated interim data from the ongoing HORIZON trial with Ygalo at the 23rd Congress of The European Hematology Association (EHA). The updated phase II-data show a clinical data set with an Overall Response Rate (ORR) of 32.1% and a Clinical Benefit Rate (CBR) of 39.3% with YgAlready a…
The European Council has decided upon a new regulation for clinical trials and in Sweden, the Medical Products Agency together with the six regional ethical review boards, missioned by the government, have made a proposal for a common collaboration structure. Today, according to the operative legAlready a subscriber Login You…
NeuroVive Pharmaceutical and Yungjin Pharm announces that the phase I clinical study in Korea within the companies' joint project KL1333, an investigational treatment for genetic mitochondrial disorders, including MELAS (Mitochondrial Myopathy, Encephalopahty, Lactic Acidosis and Stroke-like episodeAlready a subscriber Login You have read all your free articles, to continue reading…
